Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis

By LabMedica International staff writers
Posted on 16 Oct 2026

Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. More...

The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially leading to anemia, spleen enlargement, blood clots, and progression to acute myeloid leukemia. New care recommendations now emphasize broader molecular testing and earlier consultation for stem cell transplantation.

The American Society of Hematology has released evidence-based guidelines for the management of myelofibrosis, focusing on expanded molecular testing at diagnosis, early transplant referral, appropriate use of Janus kinase (JAK) inhibitors, and aspirin therapy in selected patients. The guidance aims to reduce variability in treatment decisions for this rare, progressive disease.

The recommendations support extended molecular testing to identify high-risk mutations and help guide treatment. They also advise early stem cell transplant consultation for higher-risk patients who are receiving and responding to JAK inhibitors, which can reduce spleen enlargement and other disease-related symptoms.

The guidelines include 10 recommendations covering molecular testing, transplant management, anemia treatment, JAK inhibitor use, and low-dose aspirin for patients with the JAK2 V617F mutation. JAK inhibitors are recommended for lower-risk patients with disease-related symptoms but not for higher-risk patients without such symptoms. The guidance was developed through a rigorous review process by a multidisciplinary panel that included myelofibrosis and transplant specialists, methodology experts, and a patient and caregiver with lived experience.

The guidance was published in Blood Advances on October 14, 2026. It also identifies remaining research needs, including better prediction of which patients will benefit from specific treatments, improved approaches to myelofibrosis-related anemia, and clearer timing for transplant. 

“These recommendations address questions that routinely come up for clinicians and patients managing myelofibrosis, and our hope is that they will enable hematologists to more confidently deliver better care to their patients. That said, important gaps in evidence remain, and we hope the questions we asked can help set a future research agenda to further improve care for patients with this disease,” said guideline panel chair Brady Stein, M.D., professor of medicine at Northwestern University's Feinberg School of Medicine.

Related Links
American Society of Hematology
Northwestern University's Feinberg School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.